NCT01545726View on ClinicalTrials.gov

Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Asthma
Interventions
DRUG

QAW039

QAW039 was supplied as capsules for oral administration.

DRUG

Placebo

Placebo was supplied as capsules for oral administration.

Trial Locations (1)

LE3 9QP

Novartis Investigative Site, Leicester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY